Epithelial–Mesenchymal Plasticity in Cancer: Transcriptional Regulation, Biomarker Challenges, and Emerging Therapeutic Opportunities
Cell Biochemistry and Function · 2026-07 · 44 (7)
DOI: 10.1002/cbf.70271 ↗At a glance
Übersichtsarbeit in Cell Biochemistry and Function, published online on 2026-07-17. Written by Dhrruv Shah and 1 co-authors. Institution: Department of Quality Assurance, Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS University, Mumbai, Maharashtr…. Major MEDLINE topics: Epithelial-Mesenchymal Transition, Neoplasms. Cited 1 times so far (Crossref); 119 references. The full text is freely available in PubMed Central.
Abstract (original language)
Epithelial–mesenchymal transition (EMT) is increasingly recognized as a dynamic process of epithelial–mesenchymal plasticity (EMP) rather than a binary switch between epithelial and mesenchymal phenotypes. This plasticity enables tumor cells to acquire invasive, metastatic, stem‐like, and therapy‐resistant characteristics that contribute to cancer progression and poor clinical outcomes. Despite extensive investigation, significant challenges remain in understanding the functional significance of partial EMT states, identifying robust biomarkers that capture EMT heterogeneity, and translating EMT‐targeted interventions into clinical practice. This review critically examines the molecular mechanisms governing EMT, including transcriptional regulators, signaling pathways, epigenetic modifications, and tumor microenvironmental influences. Particular emphasis is placed on hybrid epithelial/mesenchymal states, which have emerged as key drivers of metastatic fitness and therapeutic resistance. We further evaluate established and emerging EMT biomarkers, including E‐cadherin, N‐cadherin, vimentin, circulating tumor cells, and exosome‐derived signatures, highlighting their opportunities and limitations in clinical applications. Finally, we discuss current therapeutic strategies targeting EMT‐associated pathways and explain why many promising preclinical approaches have faced translational barriers. By integrating mechanistic, biomarker, and therapeutic perspectives, this review proposes that understanding and targeting epithelial–mesenchymal plasticity, rather than EMT alone, may provide a more effective framework for precision oncology and metastasis prevention.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Quality Assurance, Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS University, Mumbai, Maharashtra, India.
- Department of Pharmaceutical Chemistry, Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS University, Mumbai, Maharashtra, India.
ORCID profiles: Dhrruv Shah, Rajasekhar Reddy Alavala
Cite
APA
Shah, D., & Alavala, R. R. (2026). Epithelial–Mesenchymal Plasticity in Cancer: Transcriptional Regulation, Biomarker Challenges, and Emerging Therapeutic Opportunities. Cell Biochemistry and Function, 44(7). https://doi.org/10.1002/cbf.70271
Vancouver
Shah D, Alavala RR. Epithelial–Mesenchymal Plasticity in Cancer: Transcriptional Regulation, Biomarker Challenges, and Emerging Therapeutic Opportunities. Cell Biochemistry and Function. 2026;44(7). doi:10.1002/cbf.70271
BibTeX
@article{Shah2026,
author = {Shah, Dhrruv and Alavala, Rajasekhar Reddy},
title = {Epithelial–Mesenchymal Plasticity in Cancer: Transcriptional Regulation, Biomarker Challenges, and Emerging Therapeutic Opportunities},
journal = {Cell Biochemistry and Function},
year = {2026},
volume = {44},
number = {7},
doi = {10.1002/cbf.70271}
}
EUVIMED